Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Polypid Ltd.

Headquarters: Petah Tikva, Israel
Year Founded: 2008
Status: Public
Industry Sector: HealthTechnology
CEO: Dikla Czaczkes Akselbrad, MBA, CPA
Number Of Employees: 61
Enterprise Value: $11,783,186
PE Ratio: -0.6
Exchange/Ticker 1: NASDAQ:PYPD
Exchange/Ticker 2: N/A
Latest Market Cap: $30,318,900

BioCentury | Jan 3, 2022
Management Tracks

Robertson becomes Opthea’s first CCO

Plus: 4D Pharma, NeuShen, Mind, PolyPid and Biosion
BioCentury | Mar 17, 2021
Finance

European IPOs look to U.S. markets: Data Byte

2020’s top European biotech IPOs listed on NASDAQ, NYSE
BioCentury | Jun 26, 2020
Finance

Akouos’ first-day pop outshines peers among NASDAQ IPO trio

Fusion, PolyPid join the gene therapy company on NASDAQ, Hyloris prices IPO on Euronext
BioCentury | Feb 29, 2016
Financial News

PolyPid completes venture financing

BioCentury | Feb 25, 2016
Financial News

PolyPid's D round brings in $22M

BioCentury | Mar 30, 2015
Financial News

PolyPid withdraws IPO

Items per page:
1 - 10 of 22